This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10 Pharma Stocks Under $3

Stocks in this article: YMI DVAX AEZS BPAX ZLCS SUPG BIOD ACAD NVAX PPHM

5. SuperGen (SUPG) is a pharmaceutical company engaged primarily in the discovery and development of cancer therapies. SuperGen acquires products developed by other companies, and applies additional effort to advance these products clinically toward approval for marketing. The stock has gained 17.6% during the past one month.

Net revenue for the first quarter of 2011 was reported at $17.1 million vs. 14.4 million in the year-ago quarter. Total revenue includes royalty of $17 million compared with $14.3 million for the same period of the prior year. Net income stood at $5.5 million or 9 cents per share, increasing 17.5% from $4.7 million or 8 cents per share in the year-ago quarter.

As of March 31, 2011, the company had approximately $129.5 million in unrestricted cash, cash equivalents and current and non-current marketable securities, compared to $120.4 million at Dec. 31, 2010, as cash flow from operations rose 83.9% to $10 million. The company has a current ratio of 16.51 and no debt.

Going forward, the company expects royalty revenue for Dacogen to increase up to 5% from the prior year to range from $52 million to $55 million. However, forecasted net income has been revised to less than $12 million for 2011 from the prior guided net income of $14 million.

All the three analysts covering the stock recommend buying it. There are no sell ratings on the stock. On average, analysts estimate 133.8% upside to $6.50 in value from current levels.

6 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs